1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About

MedinCell S.A.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2002

Location

France

Primary Industry

Pharmaceuticals

About

Based in Jacou, France, and founded in 2002, MedinCell S.A. specializes in the development of injectable therapeutic products. The company's research and development phase spanned between 2002 and 2010 and launched its first product, the BEPO technology, in January 2011. The company went public in October 2018 and was listed in Euronext Paris, raising EUR 30 million and selling 4.13 million shares at EUR 7.25 per share. With the company's 130 staff members under the leadership of its current CEO, Christophe Douat, it is developing a program that could lead to the use of a long-acting injectable formulation of ivermectin in the treatment and prevention of COVID-19. MedinCell S.A. primarily develops a portfolio of long-acting injectable products in various therapeutic areas. The company combines its proprietary BEPO technology, a delivery system for long-acting injectables, with active ingredients to produce medical treatments. The BEPO technology enables a controlled and guaranteed regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters. BEPO can be administered subcutaneously for systemic exposure of active pharmaceutical ingredients or locally for targeted treatments. As of December 2020, MedinCell S.A. is aiming to make submissions for marketing approval of its long-acting COVID-19 injectable program in late 2021.
Current Investors
BNP Paribas Développement, Mirova, Credit Mutuel Equity

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.medincell.com
Company Stage
Mature
Total Amount Raised
Subscriber access only

Deals

Deals Type
Private Placement/Follow on
Private Placement/Follow on
PIPE
PIPE
IPO
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Completed MedinCell S.A. 12 May 2023
Completed MedinCell S.A. 11 Feb 2021
Completed MedinCell S.A. 16 Jun 2020
Completed MedinCell S.A. 11 Feb 2019
Completed MedinCell S.A. 08 Oct 2018
Displaying 1-5 of 6

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.